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Overall, approximately 95 percent of reported cases of vector-borne disease were 
associated with ticks, making these the most medically important group of arthropods in the 
United States.1 Despite the prevalence of tick-borne infections, the process for the diagnosis of 
this condition is not well studied. This study aims to analyze data from a pool of 100 patients who 
underwent testing for tick-borne disease in the same institution in Dover, New Hampshire during 
the most recent peak tick season of 2019. Information utilized in this study included: patient age, 
sex, location of testing (inpatient versus outpatient), diagnostic testing methods used pertaining 
to investigation of tick-borne disease, results of tick-borne panel testing, number of days to 
obtain tick panel results, symptomology, treatments pertaining to the investigation of tick-borne 
disease, and record of follow-up visits. Analyses of these data points revealed a trend that 
suggests the current diagnostic process for tick-borne disease is unnecessarily burdensome for 
patients and medical facilities. There is a need for a faster turnaround time in testing to decrease 
the need for supplemental tests and follow-up visits pertaining to the investigation of tick-borne 
diseases. This study also suggests that recognition of symptoms associated with positive results 
is paramount to improve the detection of tick-borne illnesses.  Further investigation of our 
current methods and possible future adaptations to them are critical if we are to conquer the 
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Ticks transmit the most diverse array of infectious agents of any arthropod vector. Both 
ticks and the microbes they transmit are recognized as significant threats to human and 
veterinary public health. Greater than 60% of human infectious diseases emerging between 1940 
and 2004 were zoonotic, resulting in significant global morbidity, mortality, and economic costs.2 
During 2013, 48,821 cases of autochthonous, nationally notifiable, vector-borne disease were 
reported to the United States Centers for Disease Control and Prevention (CDC). Overall, 
approximately 95 percent of reported cases of vector-borne disease were associated with ticks, 
making these the most medically important group of arthropods in the United States.1 Lyme 
disease alone accounted for almost 75 percent of all reported cases of indigenously acquired 
vector-borne disease.1 Lyme disease is the most commonly reported vector-borne illness in the 
United States. Since the institution of Nationally Notifiable surveillance efforts for Lyme disease 
in the United States in 1991, there has been a consistent increase in the number of reported 
cases. Thus, the need for targeted prevention strategies is underscored.3 Additionally from 2000 
to 2007, the incidence of infections caused by Anaplasma phagocytophilum and Ehrlichia 
chaffeensis, two tick-borne pathogens, increased linearly from 0.80 to 3.0 and 1.4 to 3.0 cases 
per million population, respectively.1 Nonetheless, the true incidence of tick-borne disease is 
likely greatly underestimated, as patients with presumed infections are rarely tested for the full 





Lyme disease, babesiosis, anaplasmosis, ehrlichiosis, and Powassan virus infection are the 
most prevalent diseases transmitted by ticks in the United States, all of which are endemic in the 
New England and upper Midwestern regions.3,5 Diagnosis of these conditions is largely reliant on 
blood testing panels that utilize a whole blood sample to detect the presence of genetic material 
of a list of organisms. The Accutix panel offered by Imugen, a reference laboratory operating in 
Norwood, Massachusetts, consists of Babesia microti DNA detection, Anaplasma 
phagocytophilium DNA testing, Ehrlichia chaffeensis DNA detection, Borrelia species DNA 
detection, and Lyme Antibody analysis.6 
 
Babesia are malaria-like protozoans that parasitize and reproduce within mammalian red 
blood cells. They have a complex life cycle involving several different stages and physical forms 
and are maintained in nature primarily via exchange between Ixodes ticks and various mammals, 
such as deer and mice.7,8 In the United States, the primary agent of human babesiosis is Babesia 
microti, which is transmitted by the bite of Ixodes scapularis, the same tick species that vectors 
Lyme disease. Cases of babesiosis caused by B. microti occur in southern New England and the 
northern Midwest. Although primarily transmitted by tick bite, babesiosis can also be acquired 
via blood transfusion and maternal-fetal transmission.8 Babesia infection can range from 
asymptomatic to life threatening. Risk factors for severe babesiosis include asplenia, advanced 
age, and impaired immune function. Severe cases can be associated with marked 
thrombocytopenia, disseminated intravascular coagulation (DIC), hemodynamic instability, acute 
respiratory distress, renal failure, hepatic compromise, altered mental status, and death.5 
Symptoms commonly seen in Babesia infection include malaise, headache, fatigue, fever, chills, 
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sweats, gastrointestinal symptoms (anorexia and nausea), and in some occurrences mild 
splenomegaly, mild hepatomegaly, and jaunice.5 Laboratory findings might indicate decreased 
hematocrit due to hemolytic anemia, thrombocytopenia, elevated serum creatinine and blood 
urea nitrogen (BUN), and/or mildly elevated hepatic transaminase values.5 Primary diagnostic 
methods are the identification of intraerythrocytic Babesia parasites via light microscope of 
blood smear, Babesia polymerase chain reaction (PCR), isolation of Babesia parasites from a 
whole blood specimen by animal inoculation, and antibody detection by indirect fluorescent 
antibody (IFA) testing for total immunoglobulin (Ig).5 The non-specific symptomology and 
unremarkable physical presentation can make babesiosis difficult to detect. Physicians should be 
alert to test for this condition with the presentation of flu-like symptoms in the summer months. 
Limitations in testing are plentiful. It may be difficult to detect in early stages in a peripheral blood 
smear, IFA antibody detection does not necessarily indicate active infection since antibodies can 
be found in serum long after infection, and PCR may not be able to detect the organism in an 
early infection if the titer is not high enough. Coinfection with Lyme disease or anaplasmosis may 
also complicate the clinical presentation and predispose the patient to more severe disease.8 
 
Another tick-borne pathogen endemic to the Northeast is Anaplasma phagocytophilum. 
This organism is an obligate gram-negative, intracellular bacterium that causes an acute febrile 
illness known as anaplasmosis or human granulocytic anaplasmosis (HGA), formerly known as 
Human Granulocytic Ehrlichiosis (HGE).5 The organism is genetically related to Rickettsia and is 
transmitted by Ixodes scapularis in the northeast United States and by Ixodes pacificus in 
California. The vector also transmits other organisms responsible for diseases such as Lyme, 
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babesiosis, ehrlichioses and Powassan encephalitis.9 A. phagocytophilum infection is acquired 
through a tick bite and disseminates to the bone marrow and spleen where it can evade 
neutrophil antimicrobial functions.9 Severe and life-threatening illness is less common with 
anaplasmosis compared to other rickettsial diseases, such as Rocky Mountain spotted fever 
(RMSF) or E. chaffeensis ehrlichiosis. While the case-fatality rate among patients who seek 
care for the illness is <1%, predictors of a more severe course include advanced age, 
immunosuppression, comorbid medical conditions, and delay in diagnosis and treatment.5 
Anaplasmosis generally presents with nonspecific symptoms such as fever, chills, malaise, 
headache, and myalgias. On rare occasions, a rash may be present. The patient may also 
report nonspecific gastrointestinal (GI) or respiratory symptoms.9 In the first weeks of infection 
laboratory findings may include a mild anemia, thrombocytopenia, leukopenia, and/or elevations 
in hepatic transaminases. Diagnosis is primarily accomplished by PCR analysis, IgG antibody titer 
by IFA, and immunohistochemical staining of organism from skin, tissue or bone marrow biopsies. 
Since antibody titers are often negative in first 7-10 days after infection and PCR is most sensitive 
during first week of infection, there are limitations in our current standards of testing for this 
condition.5 
 
Ehrlichia chaffeensis is another prevalent pathogen transmitted by Ixodes ticks. E. 
chaffeensis is an obligate intracellular Gram-negative bacterium that causes Human Monocytic 
Ehrlichiosis (HME). Signs and symptoms of ehrlichiosis typically begin within 1-2 weeks after the 
bite of an infected tick. The most common symptoms include a fever with headache, myalgia, 
and malaise, and a rash can be observed in up to 33% of patients.10 Gastrointestinal, respiratory, 
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or central nervous system involvement also may occur in more serious manifestations. Currently 
most infections are not diagnosed, but HME can be a life-threatening disease, with 
hospitalization in 41-63% of recognized cases. Severely affected patients can develop acute 
respiratory failure, renal failure, meningoencephalitis, coagulopathy, and GI bleeding. Untreated 
disease may progress to death as early as the second week of illness.10 Available diagnostic tests 
include IFA (some cross reactivity with other Ehrlichia species is possible), western blot, PCR, 
visualization of morulae (intraleukocytic clusters of bacteria) in a blood smear, 
immunohistochemical staining, and isolation.10 As with other diseases detected by these 
methods, the diagnosis of E. chaffeensis is complicated by the possibility of false positives if the 
infection level is below sensitivity parameters, particularly in microscopic and PCR methods. 
Seeing as this infection is carried by the same vector as several other tick-borne pathogens, 
diagnosis can also be affected by coinfection. Coinfecting pathogens may cause competition in 
the PCR reaction, since significantly higher concentrations of one pathogen compared with the 
others can result in the detection of only one organism.11 
 
The spirochetes include several human pathogens, including Treponema pallidum (agent 
of syphilis), Leptospira interrogans (leptospirosis), and several Borrelia spp. that cause relapsing 
fever.11 The spirochete Borrelia burgdorferi is a tick-borne obligate parasite whose normal 
reservoir is a variety of small mammals. Whereas infection of these natural hosts does not lead 
to disease, infection of humans can result in Lyme disease, as a consequence of the human 
immunopathological response to B. burgdorferi. The organism has a distinctive morphology that 
includes a spiral or wavelike body and flagella (organs of motility) enclosed between the outer 
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and inner membranes. Ticks of the genus Ixodes transmit B. burgdorferi between hosts and are 
the only natural agents through which humans have been shown to become infected. In the 
northeastern and midwestern United States, the primary tick species for human disease is Ixodes 
scapularis (the black-legged tick) and in the western states I. pacificus (the western black-legged 
tick) is the main agent of dissemination.11 In 2015, 95% of Lyme disease cases were reported from 
14 states: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, 
New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin.5 Ticks most 
frequently acquire spirochetes from infected rodents during their larval feeding. Both nymphs 
and adults occasionally feed on humans, but the small size of the nymphs makes them difficult 
to detect and, hence, more likely to feed long enough to transmit the spirochete and cause Lyme 
disease.11 In the localized stage of Lyme disease, Erythema migrans (EM), a red ring-like or 
homogenous expanding rash; is a classic indicator of Borrelia infection but may not always be 
present. More common symptoms are flu-like, such as malaise, headache, fever, myalgia, 
arthralgia, and lymphadenopathy. During the localized (early) stage of illness, Lyme disease may 
be diagnosed clinically in patients who present with an EM rash. Serologic tests may be 
insensitive at this stage. During disseminated disease, however, serologic tests should be 
positive.5 The disseminated stage is a later stage that may cause multiple secondary annular 
rashes, more severe flu-like symptoms, and lymphadenopathy. Rheumatologic, cardiac and 
neurologic manifestations are also possible at this point in infection.5 Most notable laboratory 
findings include an elevated erythrocyte sedimentation rate, mildly elevated hepatic 
transaminases, and microscopic hematuria or proteinuria. In Lyme meningitis, cerebrospinal fluid 
typically shows lymphocytic pleocytosis, slightly elevated protein, and normal glucose.5 Diagnosis 
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is primarily achieved through demonstration of diagnostic IgM or IgG antibodies in serum. A two-
step testing protocol is recommended, the first step being serological antibody analysis and the 
second being confirmation via western blot.5 Coinfection with B. microti and/or A. 
phagocytophilum should be considered in patients who present with initial symptoms that are 
more severe than are commonly observed with Lyme disease alone, especially in those who have 
high-grade fever for more than 48 hours despite appropriate antibiotic therapy or who have 
unexplained leukopenia, thrombocytopenia, or anemia. Coinfection should also be considered in 
patients whose erythema migrans skin lesion has resolved but have persistent flu-like 
symptoms.5 As will all aforementioned tick-borne pathogens, testing limitations are abundant. In 
serological testing the sensitivity and specificity are not always high enough to be detected, and 
cross-reacting immunoglobulins can be a problem in many cases. Genetic detection by PCR is 
successful only during acute infection when levels of the analyte are found at high enough 
concentrations in a blood specimen. Also, given the organism’s spirochete morphology, it can be 
difficult to observe using traditional microscopic techniques and may require special staining and 
dark microscopy.  
 
Even with the true incidence of tick-borne disease likely being greatly underestimated by 
epidemiological data, studies of trends over the last few decades have demonstrated that this 
group of infections have emerged or re-emerged in many geographical regions.12 Yet the precise 
diagnosis of many of these diseases still remains a major challenge because of the lack of 
comprehensive data available on accurate and reliable diagnostic methods.12 The diagnostic 
process is further complicated by the many limitations on the available testing strategies in 
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current practice. Identification of pathogens in biological samples has been dominated by the use 
of culture-dependent methods, conventional molecular approaches, and serological tests.12 In 
regards to tick-borne infections, these methodologies suffer from major limitations. Microscopy 
remains an important part of laboratory testing for the diagnosis of most tick-borne diseases, 
especially in resource-limited settings, but it is highly subjective and dependent on experience 
and training.12 In a modern diagnostic laboratory setting, the time constraint and expertise that 
microscopy requires prevents this method from being used on most samples unless specifically 
mandated by a physician. Cell culture procedures are time consuming, and isolation of pathogens 
is not always successful. The specificity and the sensitivity of serological tests are not always 
optimal, and cross-reactions are a common problem.12 With the upward trends the health 
community is seeing in this group of infections, it will become imperative to adapt our current 
standards of diagnosis to more accurately and quickly treat affected patient populations. To 
better understand these issues, this study aims to analyze data from a pool of 100 patients who 
underwent testing for tick-borne disease in the same institution in Dover, New Hampshire during 
the most recent peak tick season of 2019. It is here that we quantify and elaborate on the biggest 
challenges in detecting tick-borne disease with the goal of identifying possible pitfalls in current 






Materials and Methods 
This study was based on results obtained through the electronic medical records of 100 
random, fully de-identified patients who received tick panel testing through Wentworth-
Douglass Hospital in Dover, New Hampshire from April 1st to July 31st of 2019. Approval of the 
retrieval of this de-identified information was granted from the Institutional Review Boards of 
the University of New Hampshire (IRB #8122) as well as Wentworth-Douglass Hospital in August 
2019. From the time period of August 2019 to November 2019, data collection was performed 
on the WDH campus from a computer within the hospital network. Here, information was 
extracted, organized, and de-identified from the electronic medical records. The Safe Harbor 
method for de-identification of protected health, a HIPAA compliant way to remove specific 
identifiers from a data set, was used in the collection of data.13 The electronic medical records 
were obtained through multiple hospital software systems. Soarian Clinicals was used to access 
information on the testing results from all departments within the laboratory as well as outside, 
such as cardiology and radiology. Soarian Electronic Documents Manager was utilized to view all 
documentation under the patient profile, this includes intake forms, triage nurse notes, 
hospitalist notes, and treatment notes. NextGen is the software containing information on most 
outpatients such as phone call records, drug prescriptions, and follow-up appointments. SoftLab 
is the laboratory software which provided the results of the tick panel for each patient as well as 
all other laboratory testing. From a hospital device on the WDH campus, the medical history of 
100 random patients was accessed and manually transferred and simultaneously de-identified to 
an Excel spreadsheet on a private device outside the hospital network. This relevant information 
included: patient age, sex, location of testing (inpatient versus outpatient), diagnostic testing 
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methods used pertaining to investigation of tick-borne disease, results of tick-borne panel 
testing, number of days to obtain tick panel results, symptomology of the patient, treatments 
pertaining to the investigation of tick-borne disease, and record of follow-up visits pertaining to 
initial symptoms of tick-borne disease. After collection of each of these data points on all 100 
patients, analyses and generation of figures was done using the original Excel spreadsheet where 





The total number of patients analyzed (100) was partitioned into age groups. The age 
groups (in years) were under 21, 21-30, 31-40, 41-50, 51-60, 61-70, and 71+. Each age group was 
then further divided into males and females. The under 21 age group comprised a total of 7 
patients, 5 of them being female and 2 being males. The 21-30 age group totaled 18 patients, 12 
female and 6 male. The 31-40 age group comprised a total of 9 patients, 4 female and 5 male. 
The 41-50 age group consisted of 13 patients, 11 female and 2 male. The 51-60 age group 
comprised a total of 23 patients, 8 female and 15 male. The 61-70 age group totaled 17 patients, 
5 female and 12 male. The 71+ age group consisted of 13 patients, 5 female and 8 male (Fig. 1A). 
 
Data on each of the 100 patients included the location which the initial visit occurred. All 
the locations were simplified into three categories: inpatients, outpatients, and emergency room 





Figure 1. Patient Demographics. A. The age ranges for the 100 patient pool spans from under 21 
years to 71+ years. Both males and females are represented in each age range. B. The location of 
the initial visit for each patient is shown via three groups, Hospital inpatients, outpatients, and 
emergency room patients. 
 
Clinical Presentation 
Within the 100 patient pool the most commonly reported symptoms were determined. 
They included: fatigue, dizziness, vomiting, nausea, headache, myalgia, fever, and erythema 
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migrans/rash/tick bite. For each symptom the total number of patients reporting it were 
determined as well as the amount of those patients that were positive for any organism detected 
via PCR and positive for any immunoglobulins detected by serology. Seeing as patients could 
report more than one symptom, the number of patients reporting should not be considered as 
part of the total 100 but rather part of the group of all patients reporting the symptom. Nine 
patients reported fatigue, 2 of them PCR positive and 1 serology positive. Dizziness was reported 
by 6 patients, only 1 of which was positive for PCR. Vomiting was reported in 3 patients, each 
were negative in PCR and serology testing. Nausea afflicted 11 patients, 2 PCR positive and 1 
serology positive. Twenty patients reported headaches, 5 were PCR positive and 2 were serology 
positive. Forty-five patients reported myalgia as a symptom, of which 3 were PCR positive and 8 
were serology positive. Fever was reported by 27 patients, 5 were PCR positive and 3 were 
serology positive. Twenty-eight patients reported having erythema migrans, a rash, or a tick bite, 






Figure 2. Clinical Presentation. A. The most common symptoms as reported by a nurse or 
physician along with the total number of patients that reported that symptom, the number of 




As part of the diagnostic protocol, patients underwent testing other than an Accutix 
panel. Within the hospital, patients received testing results from radiology, cardiology and the 
laboratory. Within each of these departments, the most reported testing procedures were 
identified. In radiology, patients could have undergone a CT scan, an MRI, other specialty 
imaging, ultrasounds, or an X-ray. In cardiology, some patients received cardiac analysis from a 
specialist. In the laboratory, cultures of blood, urine, and other body fluids could have been done, 
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in addition to Flu testing and the Monospot which detects Epstein-Barr virus. In radiology, 14 
patients had a CT scan, 2 had MRI’s, 3 had specialty imaging, 1 had an ultrasound, and 1 had an 
X-ray. Three patients saw a cardiac specialist in the cardiology department. In the laboratory, 9 
patients had cultures, 2 got tested for the flu, and 4 were reported as having done a Monospot 
test (Fig. 3A). 
 
All 100 patients obtained results from an Accutix panel test, consists of Babesia microti 
DNA detection, Anaplasma phagocytophilium DNA testing, Ehrlichia chaffeensis DNA detection, 
Borrelia species DNA detection, and Lyme Antibody analysis. All DNA detection was performed 
via PCR, and antibody analysis was done via serology. The results of the panel were as follows: 
negative PCR for all organisms, positive PCR for 1 organism, positive PCR for 2 organisms, and 
positive Lyme antibody serology. The number of patients with those results was 89, 11, 0, and 16 
respectively. An additional result of note is a positive Borrelia PCR and positive Lyme antibody 
serology, which only 1 patient had (Fig. 3B). 
 
The Lyme antibody serology analysis detected three immunoglobulins, IgG, IgA, and IgM. 
A positive serology result could be positive for IgM, IgG, IgA, or a combination of IgM and IgG, 
IgM and IgA, IgG and IgA, or all three immunoglobulins. The number of patients with positive IgM 
only was 11, 3 patients were positive for only IgG, and 2 were positive for only IgA. Patients with 
both IgM and IgG totaled 2, while the other two combinations had no patients. One patient was 
positive for all three immunoglobulins (Fig. 3C). 
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Each of the 100 patients had an Accutix panel tested at a reference laboratory with results 
sent electronically back to the hospital laboratory. For each patient, the time (in days) between 
the blood sample draw and the testing on the sample was calculated. Most patients (33) had a 4 
day time, 22 patients had 5 days, 20 had 3 days, 10 patients had 2 days, 8 patients had 6 days, 4 





Figure 3. Diagnostic Process. A. The most common reported supplemental methods of diagnosis 
grouped by departments radiology, cariology, and laboratory, and the number of patients whose 
records indicated diagnostic procedures in each. B. Number of patients with each possible result 
from testing in both serology and PCR analysis. C. The number of patients with each combination 
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results of immunoglobulins IgG, IgA, and IgM. D. The time (days) between when the patient 
sample was sent for testing and the test was performed in a reference laboratory. 
 
Treatment Management 
The medications used to treat each of the 100 patients that were reported in the patient 
documentation can be categorized into analgesics, antibiotics, antihistamines, steroids, and 
other substances not belonging to any category. The number of patients in each was quantified. 
In the analgesics, 2 patients were given aspirin, 14 were recommended ibuprofen, 6 were given 
ketorolac, 30 received acetaminophen, and 4 were given Zofran. Of the antibiotics, 2 patients 
took amoxicillin, 2 had ceftriaxone, 35 took doxycycline, and 2 had vancomycin. The only 
antihistamine was Benadryl, which was given to 3 patients. Prednisone, the only steroids, was 












Table 1. Treatment Management. The most common reported substances for treatment 
categorized into drug classes analgesics, antibiotics, antihistamines, steroids, and other 
substances along with the number of patients who received that treatment. 
 
Incidence of Follow-Up 
Based on patient visit information on the hospital software, the incidence of follow-up 
visits at facilities in the hospital network pertaining to the investigation of tick-borne disease was 





Table 2. Incidence of Follow-up. The percentage of patients whose record indicated a follow-up 
visit pertaining to the investigation of tick-borne disease compared to the percentage of patients 




The pool of 100 patients who underwent testing related to a possible tick-borne disease 
consisted of 50 men and 50 women ranging in age from under 21 to 71+ years. Most of the 
patients, 66%, were 41 years and older, and the category with the lowest number of patients was 
the under 21 group. This is not surprising considering the group most at-risk in acquiring tick-
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borne diseases are older patients with weaker immune systems.14 The majority of patients (23%) 
were ages 51-60, and within this category was also the highest number of patients from a single 
gender, 15 males. The high number of patients in this age range could be suggestive of an at-risk 
lifestyle in this population. People between 51-60 are at or close to retirement age and likely own 
their own homes, meaning their summers may largely be spent on lawn care. Patient in this age 
range are particularly at-risk in acquiring tick-borne infections since they are still active enough 
to become exposed, but may not have strong enough immunity to protect themselves from 
infection.14 
When a patient begins the process to receive tick panel testing on their blood sample, 
they are often in one of three locations. They are either a hospital inpatient, an outpatient at a 
clinic, or an emergency room patient. Hospital inpatients are the least healthy of all these 
populations seeing as they are already in the hospital being cared for due to a different cause. 
Not surprisingly, this group of patients totals only 11 out of the 100 studied. This is most likely 
because these patients are not outside becoming exposed to ticks, but still do have symptoms 
that might warrant tick panel testing. It is the outpatients that make up a total of 49%, the most 
of any population, with emergency room patients having just a slightly lower total of 40%. These 
two populations present the most risk considering they are more likely to be spending their days 
outside becoming exposed to ticks. One reason outpatients might outnumber emergency room 
patients would be based on the preference of most patients. Most people prefer to visit a walk-
in clinic rather than face a trip to the emergency room which is usually more expensive.15 If a 
patient has only headaches or a mild rash, it is unlikely they treat this as an urgent enough issue 
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and make a trip to the hospital where longer wait times and expensive bills are real 
consequences. 
The symptomology of each patient was based on reports from nurse practitioners and 
doctors who assessed the patient and recommended or administered treatment. The most 
common symptom reported was myalgia, or muscle pain, which comprised a total of 45 patients. 
The group of patients who reported this symptom also had the highest number of serology 
positive people, 8 total, and had 3 people who were PCR positive. The next highest reported 
symptom was erythema migrans/rash/tick bite which had 28 patients total. Five of these patients 
were serology positive and 4 were PCR positive. This is interesting seeing as erythema migrans 
has long been considered a hallmark symptom of Lyme disease,16 and yet only 11 patients who 
reported this symptom and others like it were serology or PCR positive. This study may beg the 
question as to whether this clinical presentation should be given the weight that it currently holds 
in the diagnostic process. The third most commonly reported symptom was fever, which 
occurred in 27 patients, 3 being serology positive and 5 being PCR positive. Patients with fever 
and patients with a headache (20 total) were tied for most PCR positive patients at a total of 5. 
The lowest reported symptom was vomiting with 3 patients (none positive) and dizziness with 6 
patients (1 PCR positive). This information can be helpful in differentiating the likelihood of 
positive results based on symptomology. Patients presenting with myalgia were mostly serology 
positive, which is not likely reflecting a current infection but perhaps a prior infection that has 
been treated. Patients with PCR positivity indicating an acute infection were mostly comprised 
of those presenting with fever and/or headache. Fatigue was only reported in 9 patients with 2 
testing PCR positive and 1 serology positive. Considering that fatigue or malaise is a chief 
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symptom of tick-borne disease,16 it is interesting that it was reported in so few cases. This may 
indicate that more attention should be put on those suffering myalgias and fevers than those 
who are fatigued, nauseous, vomiting, or experiencing dizziness regarding tick-borne diseases.  
In addition to submitting a blood sample for Accutix panel testing, many of the 100 
patients were reported as having other supplemental diagnostic testing done in hospital 
departments. The most commonly utilized departments were radiology, cardiology, and the 
hospital laboratory. Of the testing done in radiology, CT scans were reported by the most patients 
of all the departments at 14%. In the laboratory, 9 patients had other cultures performed, 2 had 
flu testing, and 4 had a Monospot test. Three patients underwent cardiac analysis in cardiology. 
The total percentage of patients who had reported supplemental testing was 39%, meaning that 
a considerable amount of people underwent additional testing while their Accutix results were 
pending. This trend creates a large burden for the testing facility and the patients undergoing 
testing. Seeing as this testing is often done in the days before the reference laboratory performs 
the Accutix testing, this extra cost could theoretically be eliminated if the results were returned 
at a faster rate.  
Seeing as the Accutix panel is comprised of PCR analysis of four different organisms and 
a Lyme antibody serology analysis, there are several kinds of testing results that patients could 
obtain. The result belonging to most patients, 89, was negative PCR analysis. The remaining 11 
patients out of the 100 were positive in PCR for one organism. There were no patients who tested 
positive in PCR for 2 or more organisms. Of the 100 patients, 16 total tested positive in Lyme 
antibody serology. There was only one patient who tested positive for Borrelia species PCR and 
Lyme serology, which is interesting considering people with Borrelia infection are expected to 
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have positive results in both of these analyses.17 This number could indicate that it is not often 
that patients are going to reflect both active infection and immune response during testing. Most 
patients are either in an acute phase where DNA is present and antibodies are not yet detectable, 
or they are in a recovered phase where antibodies are still present but the DNA of the organism 
is not detectable.17 This information could be valuable in assessing the window period of infection 
and comparing it to when patients are most likely going to see symptoms that prompt a visit to 
their clinic for testing. 
In the patient population who tested positive in Lyme antibody serology, there are three 
immunoglobulins for which a person could be positive, IgG, IgM and IgA. The sole presence or 
combination of any (or all) of these immunoglobulins provides important diagnostic information 
which helps determine what stage of infection the patient might be in.17 In the pool of 100 
patients, most people who tested positive in serology had IgM (11 patients). IgG was only found 
in 3 patients and IgA was found in 2. Since IgM is the first antibody produced upon infection, this 
could indicate that most people who tested positive were in an early response stage of infection, 
which often occurs at least ten days after the initial exposure.18  The low prevalence of IgG 
immunoglobulins in this patient population indicates that there were not many cases of recurring 
infection, where IgG is expected to be found in higher concentrations than IgM.18 These figures 
offer a valuable insight as to the stage of infection that most patients present with at the time of 
testing.   
Since the Accutix panel testing is done at a reference laboratory outside the hospital, 
there is a wait time between when the specimen is collected and when it is tested. This time is 
expressed in days and is calculated from the laboratory reports from each of the 100 patients. 
27 
 
About one third of patients, 33 of them, had a 4 day wait time for their Accutix testing. There 
were 22 patients who had a wait time of 5 days and 20 patients who waited 3 days. Seeing as 
most patients had more than a couple days to wait for their results, it is likely that in this time 
patients underwent other testing and further investigation of their symptoms pending their panel 
results. This presents a greater economic burden to the patient, and the testing might not 
ultimately be necessary depending on the actual diagnosis the patient receives. The time and 
resources of the different departments being handed these patients while they are waiting for 
off-site results is also significant and presents a challenge for the facility.  
Of the treatment that was most commonly reported amongst the 100 patients, most can 
be categorized by drug class. These include analgesics, antibiotics, antihistamines, steroids, and 
other substances. The most noteworthy treatments were the analgesics Ibuprofen and 
Acetaminophen which were used by 14 and 30 patients respectively, and the antibiotic 
doxycycline which was prescribed to 35 patients. Fluids were either recommended or 
administered via IV to a total of 22 patients. This data reveals that the way tick-borne testing is 
treated is mostly palliative care and low-grade pain management. The most common antibiotic 
used is doxycycline which is almost always written as a 100 mg pill taken twice per day for at least 
ten days. Although doxycycline has been shown to be effective against tick-borne disease,19,20 
the problem of over-prescription must be considered. Since many patients given this antibiotic 
are prescribed in leu of Accutix results being released, there are a considerable number of 
patients taking a course of antibiotic they likely don’t need. The consequence of over-use of 
antibiotics has long been investigated as a cause of antibiotic resistance.21 If the medical 
community relies too heavily on doxycycline, it is simply a matter of time before the organisms 
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we are attempting to combat debut a mutation that allows resistance in the next tick season. 
With the prevalence of tick-borne disease today, it is likely that our treatment for this type of 
infection will have to become more targeted if we are to prevail over these pathogens in the 
future.   
The incidence of follow-up visits at facilities in the hospital network pertaining to the 
investigation of tick-borne disease was quantified. Of the 100 patients, 42% did have a 
documented follow-up visit and 58% did not. These follow-ups in 42 of the studied cases could 
have been a visit with a specialist, an appointment for scanning in radiology, a primary care 
physician visit, or an emergency room or outpatient facility visit for worsening symptoms. All of 
these types of visits pertain to the diagnostic investigation of tick-borne illness. It is important to 
consider that almost half of this small population of patients returned for a follow-up, and this 
figure is likely underestimated seeing as patients could have made an appointment outside of 
the hospital network. This high percentage of follow-ups present two problems; the first being a 
heavy financial burden on the patient and the second being the large amount of time and 
resources spent on these patients by the hospital. There are benefits to follow-ups where the 
treatment of these patients is discussed, for example when a physician is ensuring the patient 
how important it is to finish their course of antibiotics. However, these follow-ups can be 
detrimental to both the patient and the hospital facility if they are functioning as continued 
investigations in leu of tick-panel results. Supplemental testing being ordered and performed 
during these visits means there are more charges being added to the patient’s bill and more 
resources being used on this patient by the facility. If there was a quicker methodology in 
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detecting these kinds of diseases, the savings on behalf of all parties involved would be 
significant.   
 
Conclusions and Future Directions 
The predominating conclusion of this study is that investigation of tick-acquired disease 
is burdensome to the patient and the hospital facility, and studying this process to better adapt 
to this challenge will be imperative in the future of health care. This is evidenced by data 
surrounding supplemental testing, time to diagnosis, and follow-up visits. Thirty-nine percent of 
the studied patient population had supplemental testing in addition to an Accutix blood analysis 
panel. Thirty-three percent of patients waited four days to receive the results of their panel, 
which is likely the same days they underwent additional testing. Finally, 42% of patients required 
a follow-up visit in the investigation of their tick-borne illness. Between supplemental testing and 
follow-up visits taking place in the hospital, there is a significant burden placed on the facility as 
these patients await their Accutix results. The days in which patients and physicians are waiting 
for definite diagnosis are often the same days in which further investigation is taking place. 
Ultimately, the financial obligations of the patient and testing facility are maximized in our 
current process. During the peak tick seasons in New England, it would be beneficial for more 
hospital facilities to study the flow of diagnoses in patients presenting with symptomology 
suggesting tick-borne disease. There is abundant room for improvement in this process that 
would protect the resources of both the patient and the hospital.  
Another noteworthy trend that became apparent during this study was the immense 
challenge of navigating the clinical presentations of tick-borne diseases. The hallmark symptoms 
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in this category of infections are erythema migrans or bull’s eye rashes, fever, fatigue and 
malaise. The bull’s eye rash associated with Lyme disease is an observation that is rarely actually 
observed in clinical practice, and other “hallmark” symptoms like fatigue are so general to the 
scope of medical practice that they are virtually useless in a differential diagnosis. This study 
found that the most common reported symptom from patients who received positive test results 
for tick-borne infection was myalgia. This begs the question as to whether the medical 
community needs to re-visit its definition of the most common clinical presentations in tick-borne 
infections. More research to determine which symptoms are most closely related to positive test 
results is needed to best service clinicians and patients during peak tick season.  
Despite the important implications of this study, the many limitations within it must be 
acknowledged in its consideration. The patient pool size of 100 is sufficient for a small-scale 
analysis, but future studies would be most effective with larger population sizes of thousands of 
patients. The geographic limitations of this study are also of note. Seeing as data in these analyses 
came from one single hospital and its affiliating locations, it is imperative that a larger range of 
facilities be studied across the Northeast and in other areas where tick-borne illnesses are 
endemic. Continuations of studies such as this should include investigation on alternative 
methods of diagnosis and their effectiveness as viable alternatives to the current process. For 
example, new companies such as Tick Report.com are surfacing which offer mail-in tick testing 
services. The idea behind this concept is based on testing the tick directly for pathogens before 
lengthy testing is done on the patient in a hospital setting. Patients who discover a tick can elect 
to mail it to company headquarters and receive an electronic report within 72 hours with a 
complete profile on their tick.22 The information on the tick profile might indicate the presence 
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of a pathogen, at which point the patient can decide to seek further testing and possible 
treatment. Concepts such as this do have their own list of limitations, the most noteworthy being 
the small chance that a patient is able to recover a tick from the site of possible infection. 
However, the great opportunity for a more robust set of epidemiological data on the tick 
population in the Northeast is a valuable potential outcome for services such as these. Another 
option to decrease the turnaround time for tick-borne infection testing could be the 
development of adapted molecular assays. Many platforms already exist for the rapid detection 
of bacteria and viruses via polymerase chain reaction (PCR) amplification of nucleic acids. The 
GeneXpert system by Cepheid is an increasingly prevalent part of many hospital laboratories and 
features assays for Influenza, C. diff, Gonorrhea and Chlamydia, and others with turnaround 
times within a few hours23. With more molecular testing being made available at hospital level 
to eliminate the need for send-out tests, it may be worthwhile to explore adapting these methods 
for tick-borne pathogens.  The ultimate goal is reducing the time to diagnosis in these patients 
and avoid over-testing, over-prescribing, and consequently over-paying for both the patient and 
the health care facility. Further investigation of our current methods and possible future 
adaptations to them are critical if we are to conquer the diverse array of challenges presented 
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